- Home
- CUBI vs NUVB Comparison
CUBI vs NUVB Comparison
Compare CUBI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CUBI | NUVB |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUBI | NUVB |
|---|---|---|
| Price | $78.31 | $5.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $86.00 | $10.89 |
| AVG Volume (30 Days) | 326.5K | ★ 6.3M |
| Earning Date | 01-22-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.99 | N/A |
| EPS | ★ 6.26 | N/A |
| Revenue | ★ $720,354,000.00 | $26,748,000.00 |
| Revenue This Year | $14.54 | $600.69 |
| Revenue Next Year | $11.65 | $196.96 |
| P/E Ratio | $12.22 | ★ N/A |
| Revenue Growth | 12.31 | ★ 1137.19 |
| 52 Week Low | $40.75 | $1.54 |
| 52 Week High | $82.56 | $9.75 |
Technical Indicators
Market Signals| Indicator | CUBI | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 27.30 |
| Support Level | $74.84 | $5.44 |
| Resistance Level | $78.58 | $5.72 |
| Average True Range (ATR) | 2.58 | 0.44 |
| MACD | -0.34 | -0.17 |
| Stochastic Oscillator | 58.79 | 3.64 |
Price Performance
Historical ComparisonAbout CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.